Zobrazeno 1 - 10
of 83
pro vyhledávání: '"Seiki, Takashima"'
Autor:
Tomohiro Shidahara, Shozo Ohsumi, Yuichiro Miyoshi, Mina Takahashi, Seiki Takashima, Kenjiro Aogi, Norihiro Teramoto
Publikováno v:
Case Reports in Oncology, Vol 14, Iss 3, Pp 1632-1637 (2021)
Chemotherapy is often difficult to treat human epidermal growth factor receptor 2 (HER2)-positive metastatic recurrent breast cancer in the elderly, and no standard treatment has been established at this point. We experienced a case in which trastuzu
Externí odkaz:
https://doaj.org/article/674188a6bce94315b11aa61fbcff3e77
Autor:
Fumine Tsukamoto, Koji Arihiro, Mina Takahashi, Ken-ichi Ito, Shozo Ohsumi, Seiki Takashima, Takaaki Oba, Masayuki Yoshida, Kazuki Kishi, Keisuke Yamagishi, Takayuki Kinoshita
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-8 (2021)
Abstract Background The benefits of postoperative chemotherapy in patients with estrogen receptor (ER)-positive breast cancer remain unclear. The use of tumor grade, Ki-67, or ER expression failed to provide an accurate prognosis of the risk of relap
Externí odkaz:
https://doaj.org/article/3f42261e6f1d42f2bb5fcc6fdaaa5ceb
Autor:
Megumi Takaoka, Shozo Ohsumi, Yuichiro Miyoshi, Mina Takahashi, Seiki Takashima, Kenjiro Aogi, Teruhiko Shimizu, Norihiro Teramoto, Yasuko Yamamoto, Miki Okamura
Publikováno v:
Surgical Case Reports, Vol 7, Iss 1, Pp 1-5 (2021)
Abstract Background Hereditary breast and ovarian cancer (HBOC) syndrome is a susceptibility syndrome for cancers, such as breast and ovarian cancer, and BRCA1/2 are its causative genes. Annual breast-enhanced magnetic resonance imaging (MRI) is reco
Externí odkaz:
https://doaj.org/article/40509a5bfa7a41ffac779ea0f30a4b4f
Autor:
Norihiro Teramoto, Shozo Ohsumi, Tomohiro Shidahara, Seiki Takashima, Kenjiro Aogi, Yuichiro Miyoshi, Mina Takahashi
Publikováno v:
Case Reports in Oncology
Case Reports in Oncology, Vol 14, Iss 3, Pp 1632-1637 (2021)
Case Reports in Oncology, Vol 14, Iss 3, Pp 1632-1637 (2021)
Chemotherapy is often difficult to treat human epidermal growth factor receptor 2 (HER2)-positive metastatic recurrent breast cancer in the elderly, and no standard treatment has been established at this point. We experienced a case in which trastuzu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::820275a14e39e500aa50c931954e7856
http://europepmc.org/articles/PMC8647049
http://europepmc.org/articles/PMC8647049
Autor:
Miyuki Doi, Shozo Ohsumi, Sachie Shimizu, Seiki Takashima, Sachiko Kiyoto, Yuichiro Miyoshi, Mina Takahashi, Kenjiro Aogi
Publikováno v:
Cancer Research. 80:P5-14
Introduction Scalp cooling during chemotherapy infusion to mitigate hair loss for breast cancer patients is becoming popular in European and North American countries. But there is little prospective data regarding hair recovery after chemotherapy wit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b2d778b0ae92d362f700920e6e57b5c8
https://doi.org/10.1158/1538-7445.sabcs19-p5-14-21
https://doi.org/10.1158/1538-7445.sabcs19-p5-14-21
Autor:
Sachiko Kiyoto, Shozo Ohsumi, Kenjiro Aogi, Mina Takahashi, Sachie Shimizu, Seiki Takashima, Miyuki Doi
Publikováno v:
Supportive Care in Cancer
Purpose Scalp cooling during chemotherapy infusion to mitigate alopecia for breast cancer patients is becoming widespread; however, studies regarding hair recovery after chemotherapy with scalp cooling are limited. We conducted a prospective study of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::89e4fb6773ee4a14d0ca6ba9b7cbcb53
http://europepmc.org/articles/PMC8410694
http://europepmc.org/articles/PMC8410694
Autor:
Takashi Asakawa, Masahiko Ikeda, Takahiro Nakayama, Norikazu Masuda, Sho Matsumoto, Tomofumi Osako, Tsutomu Takashima, Masato Takahashi, Daisuke Shimizu, Shoichiro Ohtani, Seiki Takashima, K. Ishida, Miki Yamaguchi, Yoshinori Ito, Shigenori Nagai, Yoshifumi Komoike, Michiko Tsuneizumi
Publikováno v:
Breast Cancer Research and Treatment
Purpose In the CLEOPATRA study of patients with human epidermal growth factor receptor 2 (HER2)-positive recurrent or metastatic breast cancer, the Japanese patient subgroup did not demonstrate the improved progression-free survival (PFS) of pertuzum
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::08cdd7eb3cf9e2267cc3732e13b24924
https://doi.org/10.1007/s10549-020-05921-x
https://doi.org/10.1007/s10549-020-05921-x
Autor:
Fumikata Hara, Sachiko Kiyoto, Miwa Matsuda, Shozo Ohsumi, Miyuki Doi, Naomi Yamamura, Kenjiro Aogi, Seiki Takashima, Mina Takahashi
Publikováno v:
Supportive Care in Cancer. 29:437-443
Scalp cooling during chemotherapy infusion has been recently reported to have moderate efficacy in the mitigation of chemotherapy-induced alopecia; however, there are few reports on Asian patients. We aimed to clarify the effects of scalp cooling in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::40ce7444fb303a1059170924b1c9e7a3
https://doi.org/10.1007/s00520-020-05506-w
https://doi.org/10.1007/s00520-020-05506-w
Autor:
Yuichiro Miyoshi, Yasuko Yamamoto, Sachiko Kiyoto, Shozo Ohsumi, Mina Takahashi, Keika Kaneko, Miki Okamura, Kenjiro Aogi, Maya Uno, Seiki Takashima, Yumi Matsuyama
Publikováno v:
Nihon Nyugan Kenshin Gakkaishi (Journal of Japan Association of Breast Cancer Screening). 29:21-25
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5e563d4a8ce347d1d4418ca13e9e6d72
https://doi.org/10.3804/jjabcs.29.21
https://doi.org/10.3804/jjabcs.29.21
Autor:
Fumikata Hara, Sachiko Kiyoto, Daisuke Takabatake, Seiki Takashima, Kenjiro Aogi, Shozo Ohsumi, Norihiro Teramoto, Rieko Nishimura, Shigemitsu Takashima
Publikováno v:
Case Reports in Oncology, Vol 3, Iss 2, Pp 137-141 (2010)
It is well-known that tamoxifen increases the risk of endometrial cancer. Although metastasis to the uterus from breast cancer is uncommon, there have been some case reports on uterine metastasis. If an endometrial abnormality is detected, the differ
Externí odkaz:
https://doaj.org/article/649a35c69602498b97b076a0f4b482cb